NCT01826773View on ClinicalTrials.gov

CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Coronary Artery Disease
Interventions
DRUG

CardioPET™

CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).

Trial Locations (5)

Unknown

Dienst Nucleaire Geneeskunde, OLV Ziekenhuis Aalst, Aalst

Departement de Cardiologie, CU Saint-Luc, Brussels

Service de Medicine Nucleaire, CHU Erasme, Brussels

Nucleaire Geneesunde Gasthuisberg Leuven Hospital, Leuven

Service de Medicine Nucleaire, Centre Hospitalier Univerisataire de Liege, Belgium, Liège

Sponsors

Lead Sponsor

Fluoropharma, Inc.
All Listed Sponsors
lead

Fluoropharma, Inc.

INDUSTRY